People | June 15, 2022
ADC Therapeutics appoints David Gilman as Chief Business & Strategy Officer
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
The business is a recognized leader in managing Covid-19 and mRNA research programs
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Subscribe To Our Newsletter & Stay Updated
